Abstract-Potassium citrate, a proven Earth-based therapy to minimize calcium-containing renal stone development, is being tested in a double-blind study as a countermeasure to reduce the risk of renal stone formation in crewmembers on the International Space Station. Subjects ingest two potassium citrate or placebo pills with the last meal of the day from L-3 (days prior launch) to R+14 (days affer landing).
INTRODUCTION
The microgravity environment causes profound physiological changes on the human body. In short, no body system remains untouched from the effects of a microgravity environment. Cardiovascular de-conditioning, neurovestihular and immune system changes, and loss of bone have all been observed in humans during spaceflight.
Fluid and electrolyte changes have been documented including decreased urine output or increases in calcium, phosphate, potassium and sodium excretion. These changes directly affect the urinary biochemistry potentially increasing the risk of renal stone formation.
The development of an in-flight renal stone could have a profound impact on the health of the crewmember and the mission success. This study involves pre-, in-and post-flight 24-hour urine collections to assess the renal-stone forming potential during spaceflight and to determine bow long after flight increased risk exists. Quantitative measures of risk will be tested for the effectiveness of potassium citrate as a valid countermeasure to the altered chemical, environment exhibited during spaceflight.
Pathogenesis of Renal Stone Formation-Stones may form at any level in the urinary tract, but most arise in the kidney. Kidney stones are a common medical disease affecting approximately 5% of women and 10% of men throughout their lifetimes [2] . Men are affected more frequently than women with the peak age of onset between 20 and 30 years and possible recurrence patterns thereafter [2] . There tends to be a familial or hereditary predisposition to stone formation as well. Stones are of importance when they obstruct urinary flow or produce ulceration and bleeding, requiring medical treatment. Stones may be present without symptoms and significant renal damage may result if left untreated. Smaller stones with average diameter about 2-3 millimeters tend to he the most painful since they can lodge in the ureter and cause urine flow obstruction. Larger stones cannot enter the ureters and usually reside in the renal pelvis manifesting symptoms of hematuria (blood in the urine).
The formation of a renal stone is a complex result of numerous chemical, physical, and biochemical events. Renal stones consist of crystalline components incorporated into an organic matrix. The components of the resultant stones can he grouped into four main types of calculi formation: (1) calcium containing stones, (2) struvite stones (composed of magnesium ammonium phosphate), (3) uric acid stones, and (4) cystine stones. Calcium-containing stones account for 75% of all renal stones, and are comprised largely of calcium oxalate, or calcium oxalate mixed with calcium phosphate [2] . Some of the various processes that are thought to be involved in the formation of renal calculi include increased concentrations of insoluble Humans exposed to spaceflight and the resultant hypercalciuria [9, 10, 15, 20, 21, 23, 24] (increased calcium concentrations in urine) and the possible hypocitrahnia [22] (decreased citrate concentrations in urine) would he expected to experience an increased risk for renal stone formation.
Data has shown that immediately after spaceflight there is a decrease in urinary pH, which contributes to the greater relative supersaturation of uric acid in astronauts after spaceflight. In all situations, low urine volume is a key factor due to the urinary concentration of stone forming salts. Thus, decreased urine volumes after spaceflight also contribute to increased stone forming risk [22-241. Macromolecular Inhibitors of Calcium Oxalate Stone Formation--Calcium oxalate (CaOx) is the primary constituent of the majority of urinary calcium stone formed within the urinary space [1, 17] . Since normal urine is frequently supersaturated with respect to CaOx and crystalluria is a very common feature in healthy people [19] , urinary inhibitors of crystallization appear to have important roles in preventing urinary stone formation. The majority of the inhibition of CaOx crystal growth and aggregation in normal urine is provided by certain protein macromolecules [4, 7, 13] . Direct effects of these proteins on the process of crystallization may be protective by slowing the growth and/or aggregation of crystals and/or raising the concentration of CaOx required for spontaneous formation of new crystals. It is generally accepted that the kinetics of a CaOx crystal growth during the few minutes that elapse while passing through the nephron will not allow growth of crystals to a size sufficient to he retained by tubular obstruction [5] . Thus, growth inhihition alone appears less crucial than the increase in particle size that results from sticking to other crystals (i.e., aggregation) [8] 
30
stone formation, and in some cases, simply modifying the diet is sufficient to reduce the risk [6] . The extensive knowledge that exists from studies on Earth on how dietary alterations can affect some types of renal stone-forming potential can be used in our assessment of countermeasures for spaceflight.
Since urinary calcium is an obvious promoter of renal stone formation, early dietary studies focused on a reduction of dietary calcium intake. These studies demonstrated a reduction in urinary calcium levels but the data did not demonstrate a reduction in the rate of stone formation [3] . Evidence suggests that dietary calcium restriction may even promote stone formation, possibly by the increased absorption of oxalate in the gastrointestinal tract, since the intestinal absorption of oxalate is influenced by available calcium. A decrease in dietary calcium will result in less calcium available to form insoluble calcium oxalate in the intestine, thereby increasing oxalate absorption [ 1 I]. This would suggest that modifications to dietary calcium and oxalate would not he effective dietary countermeasures to spaceflight-induced hypercalciuria.
Potential Countermeasure for Spaceflight-The US Food and Drug Administration have approved Potassium citrate (Kcit) for the management of calcium and uric acid stone disease. This drug is capable of raising a low urinary pH and increasing the inhibitor concentration of citrate. Both of these factors are key contributors to the calcium oxalate, calcium phosphate and uric acid supersaturation observed with spaceflight. Citrate is known to act by complexing with calcium, which both decreases the concentration of ionized calcium and decreases crystal aggregation by adsorbing to the surface and blocking the active stoneforming growth sites [14] . The noted decrease in citrate levels of astronauts during and immediately after spaceflight would be expected to contribute to the increased risk of calcium oxalate and calcium phosphate stones. Thus, potassium citrate therapy could potentially minimize/alleviate this spaceflight-induced problem.
Terrestrially, renal stone sufferers have used Kcit for many years with a high percentage (70.100%) of non-recumence in previous stone-formers.
Minor gastrointestinal complaints have been reported, such as abdominal discomfort, vomiting, diarrhea, and/or nausea with a low incidence of upper gastrointestinal lesions estimated at one per 100,000 patient years. Also, hyperkalemia (elevated s e w potassium) may occur in subjects with renal disease or with potassium-sparing diuretics or acute dehydration. These risks are mitigated by: 1) providing slow-release wax matrix tables, 2) ingesting the dose with meals, 3) ingesting the tablet whole, without chewing, crushing, or sucking on the tablet, 4) limiting additional salt intake, and 5 ) encouraging high fluid intake.
Relationship to Spaceflight and Significance--Humans exposed to the microgravity environment of space undergo many physiological changes and adaptations. , A number of these changes contribute to an altered urinary environment that increases the potential for renal stone formation. A critical effect of spaceflight is the increased excretion of calcium and the negative calcium balance thought to he a result of the hone resorption process [9, 10, 20, 21] . As mentioned, about 75% of all renal stones are calciumcontaining stones; thus, the increased urinary calcium levels that have been observed during Gemini, Apollo, Skylah, and Space Life Sciences missions [9, 10, 15, 20, 21] would he expected to contribute to a greater stone-forming potential in the absence of any other changes. In addition to the observed metabolic alterations, in-flight data have shown a significant decreased fluid intake and emesis associated with space motion sickness during the early phase of spaceflight [16, 23, 24] , which leads to decreased urinary volumes as noted during the Skylab missions [9, 10] .
Maintaining the health and well being of crewmembers during spaceflight requires means of minimizing potential detrimental effects of microgravity. The Russians have reported one mission abort when a crewmemher developed a renal stone, and a number of U. S. astronauts have formed stones after flight. Based on the known increased risk crewmembers experience in microgravity, it is imperative that countermeasures he developed to alleviate or reduce the risks of renal stone formation.
Therefore, this Renal Stone Countermeasure Investigation will test the following hypotheses during its assessment and countermeasure validation on-hoard the International Space Station (ISS):
1)
Renal Stone risk will increase during spaceflight as compared to preflight assessments and will retum to preflight levels within 14 days after flight. 2) Potassium citrate will be an effective countermeasure to reduce spaceflightassociated risk for stone formation.
FLIGHT HARDWARE
Urine collection under microgravity conditions requires a unique set of flight hardware. The Urine Collection Kit (UCK) contains Urine Collection Devices (UCD) with the appropriate female or male adapters, clean wipes, and a Ziploc hag velcroed to the UCD and placed around the UCD during use for containment.
Both male and female subjects have a choice of three different adapters to use in conjunction with the UCD. Each subject has the opportunity to evaluate the adapters and determine which is most comfortable. By having persoid choices available, the subject should he able to find an interface that hest suits their unique body shape, which is critical in a microgravity environment.
The UCD consists of a one-way flow valve to prevent leakage, holds up to 1000 milliliters of fluid, and contains lmillilter of 2.5 molar Lithium Chloride (LiCI) as a volume marker. Following urine collection into the UCD, a urine aliquot is withdrawn through a sample port into a syringe tube. The sample syringe tubes contain 0.5% thymol and 1% thimerosal as preservatives that enable room temperature storage for up to one year with no loss of urinary analytes. While the preservatives are known to cause eye or respiratory irritation, they are enclosed in the sample tube and once the preservatives are diluted with urine they become non-hazardous. In order for urine to be collected fiom the UCD, an adapter is used to connect the sample tube to the UCD port. The port contains self-sealing septum, which provides closed-system access without exposing fluids to the microgravity environment (see Figure  2) . The samples are stored and returned to Earth for analysis. 
OPERATIONAL METHODS
All crewmembers participate in this study through Informed Consent. The crewmembers are randomly assigned potassium citrate or placebo pills for ingestion. Potassium citrate or placebo pills are ingested every Flight Day (FD) with the last meal of the day from Launch (L)-3 days to Return (R)+14 days. Data collections are separated into three phases: preflight, in-flight, and postflight (see Table   1 ). The. data collection schedule consists of a 48-hour dietiactivity period and a 24-hour urine collection at the latter half of that period. The protocol is similar for all the sessions, except the L-195 preflight session, known as the tolerance test. Each crewmember ingests potassium citrate or placebo daily to evaluate potential adverse effects before becoming a subject of the study.
During flight, void-by-void urines are collected into UCDs during a 24-hour period at early, mid, and late sessions during the mission. Following each urine collection, the crewmember withdraws one 7-milliliter aliquot into preserved urine sample ,tubes and stored at ambient temperature.^ The waste UCD is stowed in the UCB for disposal. Once the crew session is complete, the urinefilled UCB is transferred to a Russian Progress vehicle for disposal.
Diet, fluid, exercise, and medication are monitored 24 hours prior to and d&ng the urine collection period via the Inventory Management System (IMS) Bar Code Reader. No changes in fooafluid intake or activity level are required during the collection period. If the Bar Code Reader is not available, crewmembers record dieufluid intake and sample information in a hand written log.
Once the samples are returned to the ground, they are assayed for urinary factors associated with kidney stone formation. Dietary data are analyzed to evaluate the effects of dietary intake on the urinary biochemistry.
DlSCUSSlON/CONCLUSIONS
The objectives of this investigation include quantification of pre-, in-, and postflight renal stone risk associated with spaceflight and more importantly, the determination of potassium citrate as a countermeasure to minimize this risk.
Physiological changes such as fluid redistribution, bone demineralization, and muscle atrophy observed during previous spaceflights alter the urinary biochemistry favoring the development of urinary crystals and stone formation. The methods and hardware used in this study should increase ow understanding of these physiological changes and evaluate a countermeasure to reduce the risk of renal stones.
The formation of a renal stone on-orbit could have severe consequences for both the health of the crewmember and the mission success. In this double blind countermeasure study, the efficacy of potassium citrate to reduce the risk of stone formation will be assessed. The use of countermeasures will allow humans to live and work in microgravity, minimize the risks that are part of the readaptation process upon return to Earth's gravity, and optimize crew safety, well-being and performance.
This investigation has flown as part of the NASA Human Life Sciences research complement beginning with the ISS Increment 3 mission. To date eleven of the requested twenty subjects have completed the study. Due to the double-blind nature of the experiment, conclusions cannot be drawn until completion of the experiment. 
